New treatments are needed for severe asthmatics who do not respond to standard therapy with inhaled steroids, especially those with a “type 2 low” phenotype, such as individuals with neutrophil-predominant inflammation. This solicitation is for the development and early commercialization of an inhalational formulation of the 5A apolipoprotein A-I (apoA-I) mimetic peptide that can be administered to asthmatic subjects in Phase I clinical trials and subsequently developed into a new treatment for severe asthma.
Proposals will be due October 21, 5 pm and there will be a pre-proposal webinar on August 24, 2 pm (http://bit.ly/FY17ContractsWebinar) for companies who may be interested in applying."